Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1-2
|
| pubmed:dateCreated |
1993-5-25
|
| pubmed:abstractText |
The use of high-dose cyclophosphamide, carmustine, and etoposide (CBV) with autologous bone marrow transplantation (ABMT) results in long-term disease-free survival of about 30% in patients with relapsed Hodgkin's disease. Laboratory and clinical data show that cisplatin is synergistic with etoposide and carmustine, with non-overlapping extramedullary toxicity. Twenty-one patients with relapsed Hodgkin's disease that had progressed after both MOPP-like and ABVD-like regimens were treated with CBV plus cisplatin (90 mg/m2) and ABMT. The CR rate was 55%; the three-year disease-free and overall survival were 29% and 38% respectively; these results are comparable to prior experience with CBV. Performance status was strongly correlated with achievement of CR, survival, and time to treatment failure. Nephrotoxicity was seen in 3 patients, and ototoxicity in 1 patient. Although cisplatin could be added to CBV with minimal additional toxicity, the results obtained in this small patient population were not better than those of the earlier regimen. A larger trial in patients not previously exposed to cisplatin may better define the role of its addition to CBV.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1042-8194
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
71-7
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:8477204-Adolescent,
pubmed-meshheading:8477204-Adult,
pubmed-meshheading:8477204-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8477204-Bone Marrow Transplantation,
pubmed-meshheading:8477204-Carmustine,
pubmed-meshheading:8477204-Combined Modality Therapy,
pubmed-meshheading:8477204-Cyclophosphamide,
pubmed-meshheading:8477204-Etoposide,
pubmed-meshheading:8477204-Female,
pubmed-meshheading:8477204-Hearing Loss,
pubmed-meshheading:8477204-Hodgkin Disease,
pubmed-meshheading:8477204-Humans,
pubmed-meshheading:8477204-Kidney Diseases,
pubmed-meshheading:8477204-Male,
pubmed-meshheading:8477204-Middle Aged,
pubmed-meshheading:8477204-Prognosis,
pubmed-meshheading:8477204-Remission Induction,
pubmed-meshheading:8477204-Salvage Therapy,
pubmed-meshheading:8477204-Survival Rate,
pubmed-meshheading:8477204-Transplantation, Autologous,
pubmed-meshheading:8477204-Treatment Outcome
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.
|
| pubmed:affiliation |
University of Texas M. D. Anderson Cancer Center, Houston.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|